Zymeworks ZYME Milestone revenue — Research and development collaborations
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zymeworks's milestone revenue — research and development collaborations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zymeworks's milestone revenue — research and development collaborations?
- Zymeworks (ZYME) reported milestone revenue — research and development collaborations of $0 in Q1 2026.
- How has Zymeworks's milestone revenue — research and development collaborations changed year-over-year?
- Zymeworks's milestone revenue — research and development collaborations decreased by 100.0% year-over-year, from $14M to $0.
- What does milestone revenue — research and development collaborations mean?
- This metric represents revenue recognized from research and development collaboration agreements upon the achievement of specific clinical, regulatory, or commercial milestones. It reflects the successful progression of partnered therapeutic programs and the realization of contingent payments defined within strategic biopharmaceutical alliances. This revenue stream is a key indicator of the company's ability to validate its technology platforms through external partnerships.